Enterprise Therapeutics vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ion Channel Drug Discovery for Respiratory Disease
Enterprise Therapeutics is a UK-based drug discovery biotech targeting ion channels and mucus biology to treat cystic fibrosis, COPD, and non-CF bronchiectasis; raised ~£50M+ from Syncona and other VCs;
About
Enterprise Therapeutics is a British biotechnology company founded in 2012 and headquartered in Brighton, United Kingdom, focused on discovering and developing small-molecule drugs that target ion channels and mucus secretion biology in the airways. The company's scientific foundation draws on the biology of chloride and calcium-activated channels — particularly the TMEM16A chloride channel — which regulate mucus production and hydration in the lungs. Dysfunctional mucus clearance is a common pathological feature of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and non-CF bronchiectasis, conditions that collectively affect tens of millions of patients globally. By modulating these channels with small molecules, Enterprise Therapeutics aims to develop treatments that restore airway surface liquid and improve mucociliary clearance independent of the genetic mutation driving the disease.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Enterprise Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.